As controls, in the Her2-low MDA-MB-231 breast cancer cells and in the FcγR expressing U937 monocytic cell line, neither T-DM1 nor Trastuzumab-SB-DM1 had any effects on cell viability, similarly to the naked antibody. This evidence concerns the gene ERBB2 and breast cancer.